131 related articles for article (PubMed ID: 26642854)
21. Genetic and stochastic influences upon tumor formation and tumor types in Li-Fraumeni mouse models.
Chan CS; Sun Y; Ke H; Zhao Y; Belete M; Zhang C; Feng Z; Levine AJ; Hu W
Life Sci Alliance; 2021 Mar; 4(3):. PubMed ID: 33376133
[No Abstract] [Full Text] [Related]
22. Whole-exome analysis of a Li-Fraumeni family trio with a novel TP53 PRD mutation and anticipation profile.
Franceschi S; Spugnesi L; Aretini P; Lessi F; Scarpitta R; Galli A; Congregati C; Caligo MA; Mazzanti CM
Carcinogenesis; 2017 Sep; 38(9):938-943. PubMed ID: 28911001
[TBL] [Abstract][Full Text] [Related]
23. V(D)J recombination is not required for the development of lymphoma in p53-deficient mice.
Nacht M; Jacks T
Cell Growth Differ; 1998 Feb; 9(2):131-8. PubMed ID: 9486849
[TBL] [Abstract][Full Text] [Related]
24. Li-Fraumeni syndrome--a molecular and clinical review.
Varley JM; Evans DG; Birch JM
Br J Cancer; 1997; 76(1):1-14. PubMed ID: 9218725
[No Abstract] [Full Text] [Related]
25. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.
Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL
Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139
[TBL] [Abstract][Full Text] [Related]
26. Effects of genetic background on tumorigenesis in p53-deficient mice.
Donehower LA; Harvey M; Vogel H; McArthur MJ; Montgomery CA; Park SH; Thompson T; Ford RJ; Bradley A
Mol Carcinog; 1995 Sep; 14(1):16-22. PubMed ID: 7546219
[TBL] [Abstract][Full Text] [Related]
27. Functional studies of a novel germline p53 splicing mutation identified in a patient with Li-Fraumeni-like syndrome.
Piao J; Sakurai N; Iwamoto S; Nishioka J; Nakatani K; Komada Y; Mizutani S; Takagi M
Mol Carcinog; 2013 Oct; 52(10):770-6. PubMed ID: 22495821
[TBL] [Abstract][Full Text] [Related]
28. The effect of age at exposure on the inactivating mechanisms and relative contributions of key tumor suppressor genes in radiation-induced mouse T-cell lymphomas.
Sunaoshi M; Amasaki Y; Hirano-Sakairi S; Blyth BJ; Morioka T; Kaminishi M; Shang Y; Nishimura M; Shimada Y; Tachibana A; Kakinuma S
Mutat Res; 2015 Sep; 779():58-67. PubMed ID: 26141385
[TBL] [Abstract][Full Text] [Related]
29. DNA damage-associated dysregulation of the cell cycle and apoptosis control in cells with germ-line p53 mutation.
Goi K; Takagi M; Iwata S; Delia D; Asada M; Donghi R; Tsunematsu Y; Nakazawa S; Yamamoto H; Yokota J; Tamura K; Saeki Y; Utsunomiya J; Takahashi T; Ueda R; Ishioka C; Eguchi M; Kamata N; Mizutani S
Cancer Res; 1997 May; 57(10):1895-902. PubMed ID: 9157982
[TBL] [Abstract][Full Text] [Related]
30. Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome.
Palmero EI; Achatz MI; Ashton-Prolla P; Olivier M; Hainaut P
Curr Opin Oncol; 2010 Jan; 22(1):64-9. PubMed ID: 19952748
[TBL] [Abstract][Full Text] [Related]
31. p53 compound heterozygosity in a severely affected child with Li-Fraumeni syndrome.
Quesnel S; Verselis S; Portwine C; Garber J; White M; Feunteun J; Malkin D; Li FP
Oncogene; 1999 Jul; 18(27):3970-8. PubMed ID: 10435620
[TBL] [Abstract][Full Text] [Related]
32. Dissociation between cell cycle arrest and apoptosis can occur in Li-Fraumeni cells heterozygous for p53 gene mutations.
Delia D; Goi K; Mizutani S; Yamada T; Aiello A; Fontanella E; Lamorte G; Iwata S; Ishioka C; Krajewski S; Reed JC; Pierotti MA
Oncogene; 1997 May; 14(18):2137-47. PubMed ID: 9174049
[TBL] [Abstract][Full Text] [Related]
33. Drastic effect of germline TP53 missense mutations in Li-Fraumeni patients.
Zerdoumi Y; Aury-Landas J; Bonaïti-Pellié C; Derambure C; Sesboüé R; Renaux-Petel M; Frebourg T; Bougeard G; Flaman JM
Hum Mutat; 2013 Mar; 34(3):453-61. PubMed ID: 23172776
[TBL] [Abstract][Full Text] [Related]
34. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
[TBL] [Abstract][Full Text] [Related]
35. Novel oncogene amplifications in tumors from a family with Li-Fraumeni syndrome.
Rieber J; Remke M; Hartmann C; Korshunov A; Burkhardt B; Sturm D; Mechtersheimer G; Wittmann A; Greil J; Blattmann C; Witt O; Behnisch W; Halatsch ME; Orakcioglu B; von Deimling A; Lichter P; Kulozik A; Pfister S
Genes Chromosomes Cancer; 2009 Jul; 48(7):558-68. PubMed ID: 19378321
[TBL] [Abstract][Full Text] [Related]
36. Increased sperm aneuploidy in two male carriers of germline TP53 mutations.
Paulasova P; Diblik J; Trkova M; Macek M; Sedlacek Z
Cancer Genet; 2011 May; 204(5):278-81. PubMed ID: 21665182
[TBL] [Abstract][Full Text] [Related]
37. RNA polymerase III transcription can be derepressed by oncogenes or mutations that compromise p53 function in tumours and Li-Fraumeni syndrome.
Stein T; Crighton D; Boyle JM; Varley JM; White RJ
Oncogene; 2002 May; 21(19):2961-70. PubMed ID: 12082526
[TBL] [Abstract][Full Text] [Related]
38. Simultaneous Adrenocortical Carcinoma and Neuroblastoma in an Infant With a Novel Germline p53 Mutation.
Courtney R; Ranganathan S
J Pediatr Hematol Oncol; 2015 Apr; 37(3):215-8. PubMed ID: 25374282
[TBL] [Abstract][Full Text] [Related]
39. The TP53 gene promoter is not methylated in families suggestive of Li-Fraumeni syndrome with no germline TP53 mutations.
Finkova A; Vazna A; Hrachovina O; Bendova S; Prochazkova K; Sedlacek Z
Cancer Genet Cytogenet; 2009 Aug; 193(1):63-6. PubMed ID: 19602465
[TBL] [Abstract][Full Text] [Related]
40. Several mutant p53 proteins detected in cancer-prone families with Li-Fraumeni syndrome exhibit transdominant effects on the biochemical properties of the wild-type p53.
Srivastava S; Wang S; Tong YA; Pirollo K; Chang EH
Oncogene; 1993 Sep; 8(9):2449-56. PubMed ID: 8361758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
